Our study is the first to indicate that α−tubulin modification may contribute to ER−α restoration by the combined pentadecanoic acid and tamoxifen treatment, particularly in ER−α−under−expressing breast cancer cells. This evidence concerns the gene ESR1 and breast carcinoma.